SPONSOR
Genmab
Total Trials
2
Recruiting
2
Phases
Phase 3
Conditions studied: Platinum-resistant Ovarian CancerOvarian CancerPlatinum-sensitive Ovarian CancerPSOC
Genmab is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Platinum-resistant Ovarian Cancer, Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC.
The trial portfolio spans Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Genmab
How many clinical trials has Genmab sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Genmab, of which 2 are actively recruiting participants. These trials cover conditions including Platinum-resistant Ovarian Cancer, Ovarian Cancer, Platinum-sensitive Ovarian Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Genmab research focus on?
Genmab clinical trials span Platinum-resistant Ovarian Cancer, Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC. The research pipeline includes Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Genmab clinical trial?
To participate in a Genmab trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Genmab trials with current recruitment status updated daily.
Clinical Trials by Genmab
NCT07604766 Phase 3
Recruiting
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
Platinum-resistant Ovarian Cancer
NCT07225270 Phase 3
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Ovarian Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology